20 articles
A Phase II NCI trial testing bintrafusp alfa in metastatic urothelial carcinoma was terminated after enrolling only 2 patients.
A phase II trial explores whether the amino acid L-arginine, with or without enzyme inhibitors, can improve erectile function and quality of life after prostate cancer radiation therapy.
Amgen's siRNA therapy olpasiran targets lipoprotein(a), a stubborn cardiovascular risk factor with no approved treatments.
Small pilot study explores whether restoring gut bacteria can break the cycle of recurrent UTIs in women.
A completed Phase IIIb trial tests whether pelacarsen can safely lower Lp(a) in historically underrepresented cardiovascular disease populations.
A completed trial compares two endometrial prep strategies for IVF patients with moderate-to-severe intrauterine adhesions, a notoriously difficult fertility challenge.
Phase 3 trial of IBI306, a PCSK9 inhibitor, tests LDL-C reduction in Chinese adults with high cardiovascular risk on statin therapy.
Akeso's AK102 faces a placebo-controlled test in high-cardiovascular-risk patients already on statins and ezetimibe.
A completed Phase 4 trial from India evaluates whether ALA supplementation boosts flunarizine's migraine-prevention power in adolescents.
A Phase 2 trial tests whether a fixed-dose combination pill can safely lower LDL cholesterol in people with type 2 diabetes.
A Phase IIa trial explores whether the HIF-PHI drug daprodustat can safely replace EPO injections in hemodialysis patients with anemia.
New study shows how analyzing fluid from lungs can detect cancer mutations and guide personalized treatment decisions.
Merck's CETP inhibitor anacetrapib was evaluated alongside statin therapy to assess LDL-C lowering and HDL-C raising in hypercholesterolemia patients.
A completed clinical trial tests whether a prebiotic blend can boost Akkermansia muciniphila and support weight management in metabolic syndrome.
Phase 3 trial pits lerodalcibep against inclisiran to determine which PCSK9 inhibitor best cuts LDL in cardiovascular high-risk patients.
Phase I trial tests selective JAK3 inhibitor with improved safety profile compared to existing treatments for inflammatory conditions.
A Phase 2 trial tests once-daily oral resmetirom (MGL-3196) against placebo to reduce LDL-C in patients with inherited high cholesterol.
GlaxoSmithKline tests a novel NS5B inhibitor across four dose groups in chronic HCV patients, evaluating safety and short-term antiviral activity.
A Phase 1/2 trial explores combining KIR, PD-1, and CTLA-4 inhibitors to unlock stronger anti-tumor immunity.
Clinical trial tests whether senolytic compounds can reduce cellular aging burden and improve bone health markers in older adults.
